Back to Agenda
[V4-S1] Overview of Cancer Genome Precision Medicine in Medical Practice - Oncology Panels and CDxs -
Session Chair(s)
Yasuhiro Fujiwara, MD, PhD
Chief Executive
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
To promote precision medicine in cancer treatment, related issues are discussed and possible approaches were proposed in the report of “Consortium on Promotion for Cancer Genome Medicine” held in 2017. In this session, current status of oncology panel and CDx in Japan as well as cases in Senshin Iryo-B will be overviewed and the remaining issues for the implementation of cancer precision medicine in Japan will be discussed from industry, academia and government point of view.
Speaker(s)
Clinical Sequencing by Todai OncoPanel, a Multiplex Cancerrelated Gene Panel Testing
Katsutoshi Oda, MD, PhD
The University of Tokyo, Japan
Graduate School of Medicine
Implementation of the NGS-based test “NCC-Oncopanel” for Precision Cancer Medicine
Kuniko Sunami, MD, PhD
National Cancer Center, Japan
Department of Pathology and Clinical Laboratories
PMDA Perspectives on Oncology Panel
Reiko Yanagihara, PhD
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Deputy Review Director, Office of In Vitro Diagnostics
Kosuke Iijima
Chugai Pharmaceutical Co., Ltd., Japan
Department Manager, PHC Strategy Dept. Project & Lifecycle Management Unit
Kiyo Ishikura, PhD
PFDeNA Inc., Japan
Have an account?